Evidence map›Paper›PMID 36746538›Full record

ArticleBMJ open2023

Critical appraisal and comparison of recommendations of clinical practice guidelines for the treatment of schizophrenia in children and adolescents: a methodological survey.

Maíra Ramos Alves, Cristiane de Cássia Bergamaschi, Silvio Barberato-Filho, Daniela Oliveira de Melo, Rejane Coan Ferretti Mayer, Jardel Corrêa de Oliveira, Franciele Cordeiro Gabriel, Nigar Sekercioglu, Carmen Verônica Mendes Abdala, Luciane Cruz Lopes

Abstract read
In one paragraph

Article in BMJ open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Maíra Ramos AlvesGraduate Course in Pharmaceutical Sciences, University of Sorocaba, Sorocaba, Brazil.
Cristiane de Cássia BergamaschiGraduate Course in Pharmaceutical Sciences, University of Sorocaba, Sorocaba, Brazil.ORCID 0000-0002-6608-1806
Silvio Barberato-FilhoGraduate Course in Pharmaceutical Sciences, University of Sorocaba, Sorocaba, Brazil.
Daniela Oliveira de MeloGraduate Course in Pharmaceutical Sciences, Federal University of São Paulo, São Paulo, Brazil.ORCID 0000-0001-8613-7953
Rejane Coan Ferretti MayerGraduate Course in Pharmaceutical Sciences, University of Sorocaba, Sorocaba, Brazil.
Jardel Corrêa de OliveiraGraduate Course in Pharmaceutical Sciences, University of Sorocaba, Sorocaba, Brazil.ORCID 0000-0002-1178-2787
Franciele Cordeiro GabrielGraduate Course in Drugs and Medication, University of São Paulo, São Paulo, Brazil.ORCID 0000-0002-4375-3729
Nigar SekerciogluHealth Research Methodology, McMaster University, Mississauga, Ontario, Canada.
Carmen Verônica Mendes AbdalaPan American Health Organization, World Health Organization, São Paulo, Brazil.
Luciane Cruz LopesGraduate Course in Pharmaceutical Sciences, University of Sorocaba, Sorocaba, Brazil luslopesbr@gmail.com.ORCID 0000-0002-3684-3275

Funding

World Health Organization 001
6 · The paper itself

Abstract

introductionThe production of clinical practice guidelines (CPGs) has grown in the past years. Notwithstanding, the quality of these documents and their recommendations for the treatment of schizophrenia in children and adolescents is still unknown.

objectiveTo assess the quality of the guidelines and recommendations for the treatment of schizophrenia in this population.

methodsCPGs from 2004 to December 2020 were identified through a systematic search on EMBASE, MEDLINE, PsycINFO, PubMed, Epistemonikos, VHL, Global Index Medicus and specific CPG databases. The CPGs' quality was independently assessed by three reviewers using AGREE II and they were considered of high quality if they scored ≥60% in domains 3 and 6. The evidence classification systems were described, the quality of recommendations was assessed in pairs using AGREE-REX and the recommendations were compared.

resultsThe database search retrieved 3182 results; 2030 were screened and 29 were selected for full-text reading. Four guidelines were selected for extraction. Two CPGs were considered of high quality in the AGREE II assessment. We described the commonly agreed recommendations for each treatment phase. The pharmacological recommendations were described in all treatment phases. Scores of AGREE-REX were lower for psychosocial recommendations.

conclusionThere are still few clinical studies and CPGs regarding schizophrenia in children and adolescents. The quality of the documents was overall low, and the quality of the recommendations report has much to improve. There is also a lack of transparency about the quality of the evidence and the strength of the recommendations. PROTOCOL REGISTRATION NUMBER: CRD42020164899.

Indexed as

SchizophreniaAdolescentChildDatabases, FactualData ManagementHumanschild & adolescent psychiatrymental healthschizophrenia & psychotic disorders

Identifiers

PMID36746538
PMCPMC9906266

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.